Medullary cancer of the breast revisited
- PMID: 2085673
- DOI: 10.1007/BF01806330
Medullary cancer of the breast revisited
Abstract
Common as well as unusual, heretofore unmentioned histopathologic features observed in 336 typical and 273 atypical medullary breast cancers from 6404 patients enrolled in various stage I and II protocols of the National Surgical Adjuvant Breast and Bowel Projects (NSABP) are presented. Both medullary types exhibited comparable pathologic findings, except for the infiltrative border and/or slight or absent tumor lymphoid infiltrate which by definition characterize the atypical form. Both also demonstrated a similar, high proclivity to be aneuploid, and to lack estrogen and progesterone receptors and nodal metastases. After appropriate statistical adjustments, survival (analyzed for 198 patients with typical and 149 with atypical medullary cancers) was found to be better for untreated, node-negative and node-positive patients treated with L-PAM + 5Fu who had typical medullary cancers than those with the NOS histologic type. The magnitude of this difference was 6% at 5 and 17% at 10 years post-operatively (cumulative odds = 1.81 with a 95% confidence interval of 1.08 - 3.3) for the former group, and 4% at 5 and 16% at 10 years (cumulative odds = 1.56 with a 95% confidence interval of 1.08 - 2.23) for the latter. Survival was comparable for patients with atypical medullary and NOS types in both situations. No clear difference in survival was found in untreated, positive node patients with the 3 histologic types examined, although the sample sizes in this subset were relatively small. This information as well as other pertinent considerations indicate that the prognosis of typical medullary cancer is not as 'good' as previously perceived. It is also concluded that there is insufficient evidence at present to exclude the atypical medullary variant as a histologic type of breast cancer.
Similar articles
-
Pathologic findings from the National Surgical Adjuvant Breast and Bowel Projects (NSABP). Prognostic discriminants for 8-year survival for node-negative invasive breast cancer patients.Cancer. 1990 May 1;65(9 Suppl):2121-8. doi: 10.1002/1097-0142(19900501)65:9+<2121::aid-cncr2820651408>3.0.co;2-m. Cancer. 1990. PMID: 2328478
-
Prognostic factors in NSABP studies of women with node-negative breast cancer. National Surgical Adjuvant Breast and Bowel Project.J Natl Cancer Inst Monogr. 1992;(11):151-8. J Natl Cancer Inst Monogr. 1992. PMID: 1344974
-
The prognostic value of p53 and c-erb B-2 immunostaining is overrated for patients with lymph node negative breast carcinoma: a multivariate analysis of prognostic factors in 613 patients with a follow-up of 14-30 years.Cancer. 2000 Feb 15;88(4):804-13. doi: 10.1002/(sici)1097-0142(20000215)88:4<804::aid-cncr11>3.0.co;2-y. Cancer. 2000. PMID: 10679650
-
[Prognostic factors in breast cancer and their consequences for therapeutic decisions].Chirurg. 1992 Jun;63(6):461-8. Chirurg. 1992. PMID: 1643982 Review. German. No abstract available.
-
HER2 as a prognostic factor in breast cancer.Oncology. 2001;61 Suppl 2:67-72. doi: 10.1159/000055404. Oncology. 2001. PMID: 11694790 Review.
Cited by
-
Amplification of Genomic DNA for Decoy Receptor 3 Predicts Post-Resection Disease Recurrence in Breast Cancer Patients.World J Oncol. 2014 Feb;5(1):14-23. doi: 10.14740/wjon764w. Epub 2014 Mar 11. World J Oncol. 2014. PMID: 29147372 Free PMC article.
-
A methyl-deviator epigenotype of estrogen receptor-positive breast carcinoma is associated with malignant biology.Am J Pathol. 2011 Jul;179(1):55-65. doi: 10.1016/j.ajpath.2011.03.022. Epub 2011 May 13. Am J Pathol. 2011. PMID: 21641572 Free PMC article.
-
Medullary carcinoma of the breast: a population-based perspective.Med Oncol. 2011 Sep;28(3):738-44. doi: 10.1007/s12032-010-9526-z. Med Oncol. 2011. PMID: 20390465 Free PMC article.
-
Clinicopathologic characteristics at diagnosis and the survival of patients with medullary breast carcinoma in China: a comparison with infiltrating ductal carcinoma-not otherwise specified.World J Surg Oncol. 2013 Apr 22;11:91. doi: 10.1186/1477-7819-11-91. World J Surg Oncol. 2013. PMID: 23607710 Free PMC article.
-
Competing Risk Analyses of Medullary Carcinoma of Breast in Comparison to Infiltrating Ductal Carcinoma.Sci Rep. 2020 Jan 17;10(1):560. doi: 10.1038/s41598-019-57168-2. Sci Rep. 2020. PMID: 31953417 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Medical
Miscellaneous